CUTAQUIG 165 mg/ml solution for injection
*Company:
Octapharma LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 22 November 2023
File name
20231108_81x_PIL_IE_09.08_en.pdf
Reasons for updating
- Removal of Black Inverted Triangle
- Change to date of revision
Updated on 22 November 2023
File name
20231108_81x_PIL_IE_09.08_en.pdf
Reasons for updating
- Removal of Black Inverted Triangle
- Change to date of revision
Updated on 22 November 2023
File name
20231117_81x_SPC_IE_09.08_en.pdf
Reasons for updating
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 22 November 2023
File name
20231117_81x_SPC_IE_09.08_en.pdf
Reasons for updating
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 25 August 2023
File name
20230822_81x_SPC_IE_08.07_en.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 25 August 2023
File name
20230822_81x_PIL_IE_08.07_en.pdf
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Updated information on infusion rate
Updated safety information - side effects
Updated on 25 August 2023
File name
20230822_81x_SPC_IE_08.07_en.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 06 June 2022
File name
Cutaquig SmPC IE 20220505.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 04 May 2022
File name
Cutaquig PIL IE 20220318.pdf
Reasons for updating
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 04 May 2022
File name
Cutaquig SmPC IE 20220318.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 15 December 2021
File name
Cutaquig IE PIL 20210611.pdf
Reasons for updating
- New PIL for new product
Updated on 15 December 2021
File name
Cutaquig SPC IE 20210420.pdf
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 15 December 2021
File name
Cutaquig SPC IE 20210420.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Octapharma Ltd
Address:
MAH: Octapharma (IP) SPRL, Allée de la Recherche 65, 1070 Anderlecht, Belgium, (Local Agent: Octapharma Ltd, Glassworks House, 32 Shudehill, Manchester, Lancashire, M4 1EZ)Medical Information E-mail:
medinfo.uk@octapharma.comTelephone:
+44 (0)161 837 3770Website:
https://www.octapharma.co.uk